ANVS · XBRL financial data

Annovis Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ANVS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Research and development	13,838	8,905*	6,515	5,785	2,690	4,999*	5,012	5,162	6,291	8,751*	16,720	12,007
General and administrative	1,026	1,538*	1,295	1,977	1,698	1,736*	1,271	1,110	1,144	955*	1,292	2,370
Total operating expenses	14,863	10,442*	7,810	7,763	4,388	6,735*	6,283	6,271	7,435	9,706*	18,012	14,378
Operating income (loss)	(14,863)	(10,442)*	(7,810)	(7,763)	(4,388)	(6,735)*	(6,283)	(6,271)	(7,435)	(9,706)*	(18,012)	(14,378)
Interest income	147	66*	44	26	135	126*	188	191	152	168*	138	160
Income tax expense (benefit)	0	—	0	0	0	—	0	0	0	0*	0	0
Net income (loss)	(14,717)	(22,213)*	(1,067)	(5,020)	(12,638)	(5,865)*	(5,537)	(6,220)	(7,263)	(9,834)*	(17,606)	(14,821)
Earnings per share, basic USD per share	(1.63)	(2.24)*	(0.10)	(0.44)	(0.97)	(0.43)*	(0.32)	(0.32)	(0.37)	(0.39)*	(0.63)	(0.40)
Earnings per share, diluted USD per share	(1.63)	(2.24)*	(0.72)	(0.44)	(0.97)	—	(0.32)	(0.32)	(0.37)	(0.39)*	(0.63)	(0.40)
Weighted average shares, basic thousands of shares	9,012	9,915*	10,625	11,308	12,976	13,795*	17,431	19,486	19,685	25,526*	27,848	37,519
Weighted average shares, diluted thousands of shares	9,012	9,915*	10,825	11,308	12,976	13,808*	17,431	19,486	19,685	25,526*	27,848	37,519

Fiscal quarters (ANVS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,355	5,755	3,137	3,998	12,637	10,552	22,236	17,130	15,286	19,532	14,219	18,729
Total current assets	10,223	10,208	7,813	—	—	—	—	—	—	—	—	—
Total assets	10,223	10,208	7,813	5,046	14,362	13,926	26,737	21,455	17,189	21,082	16,244	22,037
Accounts payable	1,926	1,293	4,107	3,395	4,099	2,306	1,370	974	2,112	2,591	5,276	3,327
Total current liabilities	3,565	4,279	4,870	4,057	5,391	3,881	2,504	2,805	3,734	3,635	12,791	6,359
Total liabilities	3,565	17,959	11,167	6,797	7,298	4,618	2,683	3,124	4,033	4,230	13,118	26,292
Accumulated deficit	(88,046)	(110,259)	(111,326)	(116,346)	(128,985)	(134,849)	(140,387)	(146,607)	(153,869)	(163,704)	(181,310)	(196,131)
Total stockholders' equity	6,658	(7,751)	(3,354)	(1,751)	7,064	9,308	24,054	18,330	13,156	16,851	3,126	(4,255)
Total liabilities and equity	10,223	10,208	7,813	5,046	14,362	13,926	26,737	21,455	17,189	21,082	16,244	22,037
Common shares outstanding (cover page) thousands of shares	10,262	11,011	11,171	13,054	13,797	19,486	19,486	19,486	26,503	28,355	34,647	42,606

Fiscal quarters (ANVS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(14,717)	(22,213)*	(1,067)	(5,020)	(12,638)	(5,865)*	(5,537)	(6,220)	(7,263)	(9,834)*	(17,606)	(14,821)
Stock-based compensation	632*	882*	365	1,597*	393*	1,482*	500	497*	445*	357*	183	1,609*
Net cash from operating activities	(9,370)*	(9,365)*	(7,033)	(3,375)*	(3,201)*	(8,285)*	(8,099)	(5,106)*	(3,488)*	(8,927)*	(9,012)	(21,914)*
Proceeds from issuing common stock	0*	8,315*	3,875	4,236*	4,355*	6,201*	—	—	—	—	—	—
Net cash from financing activities	0*	8,765*	4,415	4,236*	11,840*	6,201*	19,783	0*	1,644*	13,173*	3,698	26,423*
Net change in cash	(9,370)*	(600)*	(2,618)	861*	8,639*	(2,085)*	11,684	(5,106)*	(1,844)*	4,246*	(5,313)	4,510*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
BriaCell Therapeutics	9,852	not reported	(5,959)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.